At the early phase of malignancy TGFβ acts to suppress cell proliferation and stimulate apoptosis, but at the later stages it can promote tumorigenesis via induction of epithelial-mesenchymal transition (EMT) and resistance to anti-cancer drugs [63, 64]. This evidence concerns the gene TGFB1 and cancer.